Answers are grounded in this paper and cite their sources.
Review explores RSV's immunopathology and immune responses, suggesting gaps hinder countermeasures.
RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus-host interactions and immunity contribute to the lack of biological countermeasures. This review updates the current understanding of RSV immunity and immunopathology with a focus on interferon responses, animal modeling, and correlates of protection.
No takes yet. Share an insight, caveat, or question.
Bergeron et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: